Featured News
May 24, 2024
Many Bright Ideas Technologies Inc. Reports Financial Results for Q1, 2024.
April 19, 2024
Many Bright Ideas Technologies Inc. Reports Audited Financial Results for 2023.
November 24, 2023
Many Bright Ideas Technologies Inc. Reports Financial Results for Q3, 2023.
August 25, 2023
Many Bright Ideas Technologies Inc. Reports Financial Results for Q2, 2023.
May 26, 2023
Many Bright Ideas Technologies Inc. Reports Financial Results for Q1, 2023.
April 21, 2023
Many Bright Ideas Technologies Inc. Reports Audited Financial Results for 2022.
November 25, 2022
Many Bright Ideas Technologies Inc. Reports Financial Results for Q3, 2022.
August 26, 2022
Many Bright Ideas Technologies Inc. Reports Financial Results for Q2, 2022.
April 22, 2022
Med BioGene Inc. Reports Audited Financial Results for 2021
November 26, 2021
Med BioGene Inc. Reports Financial Results for Q3, 2021.
August 27, 2021
Med BioGene Inc. Reports Financial Results for Q2, 2021.
March 25, 2021
Med BioGene Inc. Reports Audited Financial Results for 2020.
November 06, 2020
Med BioGene Inc. Reports Financial Results for Q3, 2020.
April 29, 2020
Med BioGene Inc. Reports Audited Financial Results for 2019.
November 29, 2019
Med BioGene Inc. Reports Financial Results for Q3 2019.
April 16, 2019
Med BioGene Inc. Reports Audited Financial Results for 2018.
November 09, 2018
Med BioGene Inc. Reports Financial Results for Q3, 2018.
August 28, 2018
Med BioGene Inc. Reports Financial Results for Q2, 2018.
April 30, 2018
Med BioGene Inc. Reports Audited Financial Results for 2017.
November 22, 2017
Med BioGene Inc. Reports Financial Results for Q3 2017.
June 21, 2015
From activist to CEO, how Iain Weir Jones landed the top job at Med Bio-Gene
September 05, 2014
Directors Nominated By Dissident Shareholder Elected At Annual General Meeting
September 04, 2014
Med BioGene Announces Receipt of Proxies for Upcoming Annual and Special Meeting
August 06, 2014
Med BioGene Announces Director Nominations and Postponement of Annual and Special Meeting
| Welcome to Med BioGene
Med BioGene’s lead test under development is GeneFx® Lung (formerly, LungExpress Dx), a proprietary gene expression-based test to improve upon staging for identifying those patients with early-stage non-small-cell lung cancer (NSCLC) who, following surgical removal of their tumor, are at higher and lower risks of mortality. In an initial study of patient specimens from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial, published in the Journal of Clinical Oncology, patients classified by GeneFx Lung as higher risk benefited from adjuvant chemotherapy, and those classified as lower risk did not benefit and may have experienced a detrimental effect from adjuvant chemotherapy. GeneFx Lung was subsequently validated in predicting patient mortality in four independent studies involving data from tumor specimens totaling 676 untreated early-stage NSCLC patients. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. On April 15, 2011, Precision Therapeutics, Inc. and Med BioGene closed their commercialization agreement. The agreement provides to Precision exclusive global rights to develop and commercialize GeneFx Lung. For more information on Precision Therapeutics, please see www.precisiontherapeutics.com. |
|
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer